Oregon Public Employees Retirement Fund lifted its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) by 12.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,298 shares of the medical equipment provider's stock after buying an additional 1,276 shares during the quarter. Oregon Public Employees Retirement Fund's holdings in BioLife Solutions were worth $257,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Millennium Management LLC boosted its stake in BioLife Solutions by 45.3% during the second quarter. Millennium Management LLC now owns 1,560,137 shares of the medical equipment provider's stock worth $21,545,000 after acquiring an additional 486,631 shares in the last quarter. State Street Corp boosted its stake in BioLife Solutions by 26.1% during the second quarter. State Street Corp now owns 1,270,364 shares of the medical equipment provider's stock worth $17,544,000 after acquiring an additional 263,021 shares in the last quarter. Gagnon Securities LLC boosted its stake in BioLife Solutions by 50.6% during the second quarter. Gagnon Securities LLC now owns 571,679 shares of the medical equipment provider's stock worth $7,895,000 after acquiring an additional 192,173 shares in the last quarter. Northern Trust Corp boosted its stake in BioLife Solutions by 78.9% during the second quarter. Northern Trust Corp now owns 363,659 shares of the medical equipment provider's stock worth $5,022,000 after acquiring an additional 160,432 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in BioLife Solutions by 549.3% during the second quarter. Renaissance Technologies LLC now owns 179,200 shares of the medical equipment provider's stock worth $2,475,000 after acquiring an additional 151,600 shares in the last quarter. Hedge funds and other institutional investors own 89.82% of the company's stock.

Analyst Ratings Changes

BLFS has been the topic of several research reports. StockNews.com raised shares of BioLife Solutions to a "sell" rating in a research note on Monday, November 21st. Stephens dropped their target price on shares of BioLife Solutions to $31.00 in a research note on Wednesday, November 16th.

BioLife Solutions Trading Down 1.3 %

BioLife Solutions (NASDAQ:BLFS – Get Rating) last released its quarterly earnings data on Wednesday, November 9th. The medical equipment provider reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). BioLife Solutions had a negative net margin of 67.70% and a negative return on equity of 7.50%. The company had revenue of $40.75 million for the quarter, compared to analysts' expectations of $41.63 million. On average, equities research analysts expect that BioLife Solutions, Inc. will post -0.63 EPS for the current fiscal year.

Insider Activity

In other BioLife Solutions news, EVP Aby J. Mathew sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $17.77, for a total transaction of $177,700.00. Following the completion of the sale, the executive vice president now directly owns 252,826 shares of the company's stock, valued at $4,492,718.02. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CRO Marcus Schulz sold 1,000 shares of the firm's stock in a transaction dated Monday, January 23rd. The shares were sold at an average price of $25.02, for a total value of $25,020.00. Following the completion of the sale, the executive now owns 43,437 shares in the company, valued at approximately $1,086,793.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Aby J. Mathew sold 10,000 shares of the firm's stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $17.77, for a total transaction of $177,700.00. Following the completion of the sale, the executive vice president now owns 252,826 shares of the company's stock, valued at approximately $4,492,718.02. The disclosure for this sale can be found here. Insiders sold 113,718 shares of company stock valued at $2,466,734 over the last three months. Insiders own 3.30% of the company's stock.

BioLife Solutions Profile

(Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Featured Stories

• Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating).

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.